Abstract
The pharmaceutical manufacturer has a duty to provide adequate warning to the prescribing physician of dangerous side effects of pharmaceutical products, not only by a written warning on product labels/inserts but also through the detail person. This paper provides an overview of the five areas of liability and discusses implications for training and monitoring the pharmaceutical sales force.
Get full access to this article
View all access options for this article.
References
1.
Section 402A of 2 Restatement of the Law 2d, Torts (1965 ).
2.
Comment K to Section 402A.
3.
Reyes v. Wyeth Laboratories (5th Cir. 1974 ), 498 F.2d. 1264.
4.
Wooderson v. Ortho Pharmaceutical Corp., 681 P.2d. 1038 (Kan. 1984 ).
5.
Toole v. Richardson-Merrell, Inc., 60 Cal. Rptr. 398 (1967 ).
6.
Brochu v. Ortho Pharmaceutical Corp., 642 F.2d. 652 (1981 ).
7.
Sterling Drug, Inc. v. Yarrow, 408 F.2d. 978 (1969 ).
8.
Hoffman v. Sterling Drug, Inc., 485 F.2d. 132 (1973 ).
9.
Crocker v. Winthrop Laboratories, Division of Sterling Drugs, Inc., 514 S.W.2d. 429.
10.
Hillard v. A. H. Robins Co., 196 Cal. Rptr. 117 (1983 ).
11.
Bladino v. Castagna, Ciba-Geigy Corporation, and Morris Park Pharmacy, 478 A.2d. 807 (1984 ).
12.
Stevens v. Parke, Davis & Company, 507 P.2d. 653 (1973 ).
13.
Kessler
DA
. “Drug Promotion and Scientific Exchange.”
New Eng J Med.
1991 ;325 (3 ):201 .
14.
Taylor
MR
. Drug Regulation, Off-Label Uses, and CME—Reconciling Competing Values . Arlington, VA : Food and Drug Law Institute ; Feb 26, 1992 .
15.
Whitley v. Cubberly, 210 S.E.2d. 289 (1974 ).
16.
Incollingo v. Ewing, 282 A.2d. 206 (1971 ).
17.
Salmon v. Parke, Davis and Company, 520 F.2d. 1359 (1971 ).
18.
Formella v. Ciba-Geigy Corp., 300 N.W.2d. 356 (1981 ).